# Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults

> **NCT05842798** · PHASE1 · COMPLETED · sponsor: **Zhuhai Trinomab Pharmaceutical Co., Ltd.** · enrollment: 28 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** TNM002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05842798
- **Lead sponsor:** Zhuhai Trinomab Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-15
- **Primary completion:** 2022-02-24
- **Final completion:** 2022-02-24
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05842798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05842798, "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Chinese Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05842798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*